KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Debt (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Total Debt data on record, last reported at $5.4 billion in Q4 2025.

  • For Q4 2025, Total Debt fell 12.28% year-over-year to $5.4 billion; the TTM value through Dec 2025 reached $5.4 billion, down 12.28%, while the annual FY2025 figure was $5.4 billion, 12.28% down from the prior year.
  • Total Debt reached $5.4 billion in Q4 2025 per JAZZ's latest filing, roughly flat from $5.4 billion in the prior quarter.
  • Across five years, Total Debt topped out at $6.5 billion in Q2 2021 and bottomed at $1.9 billion in Q1 2021.
  • Average Total Debt over 5 years is $5.6 billion, with a median of $5.7 billion recorded in 2023.
  • Peak YoY movement for Total Debt: skyrocketed 240.53% in 2021, then fell 12.28% in 2025.
  • A 5-year view of Total Debt shows it stood at $6.0 billion in 2021, then fell by 5.38% to $5.7 billion in 2022, then decreased by 0.2% to $5.7 billion in 2023, then increased by 6.93% to $6.1 billion in 2024, then fell by 12.28% to $5.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $5.4 billion in Q4 2025, $5.4 billion in Q3 2025, and $5.4 billion in Q2 2025.